Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics held its 2026 Annual Meeting of Stockholders, where holders of common stock as of the April 7, 2026 record date could vote. As of that date, 103,071,889 shares of common stock were issued and outstanding.
Stockholders elected Class II directors Tomas Kiselak and Jennifer K. Moses to serve until the 2029 annual meeting. Kiselak received 72,363,500 votes for and 14,475,646 withheld, while Moses received 86,378,842 for and 460,304 withheld, with 6,733,104 broker non-votes for each.
Stockholders ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 92,866,008 votes for. They also approved, on an advisory basis, executive compensation and indicated a preference to hold the advisory say-on-pay vote every year, which the board has adopted.
Viridian Therapeutics, Inc. has fully repaid its outstanding term loan, prepaying approximately $55.1 million on May 27, 2026 under its Loan and Security Agreement with Hercules Capital and other lenders. This amount covered all remaining principal, accrued interest, fees, costs and expenses, so all obligations under the agreement were satisfied and discharged.
The Loan Agreement, originally allowing aggregate maximum borrowings of up to $300 million, had funded $50 million to the company. That Term Loan carried a floating interest rate between 8.95% and 9.45% per year and was scheduled to run with interest-only payments into October 2029 or potentially October 2030, with final maturity on October 1, 2030. By paying it off early, Viridian eliminated this high-cost debt and terminated the lending arrangements several years ahead of maturity.
Viridian Therapeutics has signed a Commercial Manufacturing Services Agreement with WuXi Biologics to produce veligrotug drug substance and drug product for commercial use if the therapy is approved. WuXi will act as a non-exclusive supplier, allowing Viridian to use other manufacturers as well.
The deal uses rolling monthly volume forecasts, with a portion becoming a binding purchase commitment, and relies on volume-based pricing. Service fees remain fixed until December 31, 2026, then may be adjusted annually. The agreement runs for an initial five-year term with automatic five-year renewals and includes customary provisions on quality, regulatory compliance, confidentiality, and termination for material breach, insolvency, or certain adverse legal changes.
Viridian Therapeutics, Inc. ownership filing shows Bellevue Group and its wholly owned subsidiary Bellevue Asset Management AG report 6,726,144 shares of Common Stock, representing 6.6% of the class as of 03/31/2026. The percentage is calculated using 102,458,094 shares deemed outstanding.
The statement is filed jointly by Bellevue Group AG and BAM AG, with shared voting and dispositive power over the disclosed shares.
Viridian Therapeutics insider entities reported a large open-market share purchase. On May 11, 2026, Fairmount Healthcare Fund II L.P. bought 1,176,470 shares of Viridian common stock at $17.00 per share in an open-market transaction. After this trade, the fund’s indirect holdings reported in the filing totaled 5,090,928 shares.
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the shares held by Fairmount Healthcare Fund II L.P., but each disclaims beneficial ownership except to the extent of any pecuniary interest.
Fairmount Funds Management LLC and affiliates updated their ownership disclosure for Viridian Therapeutics, Inc. after a new share purchase. The reporting persons now have voting and dispositive power over 17,201,800 shares of common stock, representing 14.04% of Viridian’s outstanding common stock as of May 11, 2026. This position includes 5,090,928 common shares and 12,110,872 shares issuable upon conversion of Series A and Series B Non-Voting Convertible Preferred Stock, each series subject to a 19.99% beneficial ownership limitation. On May 11, 2026, Fairmount Healthcare Fund II bought 1,176,470 common shares at $17 per share in an underwritten public offering for an aggregate price of $19,999,990, funded with working capital, and agreed to a 60‑day lock-up on sales from the date of the company’s final prospectus supplement.
Viridian Therapeutics completed two major financings, issuing $250,000,000 of 1.75% Convertible Senior Notes due 2032 and closing a public equity offering of 7,352,942 common shares at $17.00 per share.
The notes pay 1.75% interest semiannually and are convertible at an initial rate of 40.5680 shares per $1,000 principal amount, implying a conversion price of about $24.65 per share, with potential increases upon certain “Make-Whole Fundamental Change” events. Net proceeds from the convertible notes were approximately $242.0 million.
The equity offering generated net proceeds of about $117.0 million. Viridian plans to use combined proceeds to repay all outstanding debt under its Hercules Capital loan, fund market expansion studies for its thyroid eye disease franchise, advance earlier-stage R&D, and for working capital and other general corporate purposes.
Viridian Therapeutics received a Schedule 13G disclosure reporting a 5,417,660-share position (5.30% of the class) held by Deep Track entities and David Kroin. The filing states the position reflects 102,206,571 shares outstanding as of February 20, 2026. The reporting persons indicate shared voting and dispositive power over the 5,417,660 shares; sole voting and dispositive power are reported as 0. The filing is a joint Schedule 13G by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin and includes a parent/subsidiary attribution note naming Deep Track Capital, LP as the relevant entity.
Viridian Therapeutics is offering $225.0 million aggregate principal amount of 1.75% convertible senior notes due May 15, 2032, with an underwriter option for an additional $25.0 million. The notes carry an initial conversion rate of 40.5680 shares per $1,000 (initial conversion price ~$24.65 per share), pay interest semi-annually at 1.75%, and may be settled in cash, shares or a combination at the company’s election. The offering is concurrent with a separate public equity offering (aggregate of $125.0 million, or up to $143.75 million if the option is exercised) and Viridian expects to use proceeds, together with the concurrent equity proceeds, to repay the Hercules Loan and fund R&D, market expansion studies and general corporate purposes. The supplement also discloses positive topline REVEAL-2 phase 3 results for elegrobart and an anticipated BLA submission in Q1 2027.
Viridian Therapeutics is offering 7,352,942 shares of common stock at a public offering price of $17.00 per share, expected to raise approximately $117.0 million in net proceeds before expenses (assuming no exercise of the underwriters' option).
Concurrently, Viridian is conducting a separate Concurrent Convertible Notes Offering of 1.75% convertible senior notes due 2032 with an aggregate principal amount of $225.0 million (or $250.0 million if the underwriters’ option is exercised). The company intends to use proceeds to repay the Hercules loan, fund market expansion studies for its TED franchise and advance R&D, and for working capital and general corporate purposes.